Basilea Pharmaceutica AG Balance Sheet

Financials in millions CHF. Fiscal year is January - December.

Millions CHF. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	128.37	120.71	59.93	84.66	53.7	60.75
Short-Term Investments	-	-	-	-	95	101.02
Cash & Short-Term Investments	128.37	120.71	59.93	84.66	148.7	161.77
Cash Growth	103.87%	101.41%	-29.21%	-43.07%	-8.08%	25.38%
Accounts Receivable	16.64	8.88	27.89	33.15	24.95	8.71
Other Receivables	40.69	49.31	30.26	28.55	39.5	23.68
Receivables	57.32	58.18	58.15	61.7	64.45	32.39
Inventory	22.63	31.61	26.41	24.24	22.78	21.19
Restricted Cash	4.36	3.85	4.39	1.91	1.25	5.51
Other Current Assets	4.8	6.56	3.27	2.85	3.88	2.66
Total Current Assets	217.47	220.91	152.15	175.36	241.07	223.53
Property, Plant & Equipment	17.53	18.98	20.55	21.57	2.92	5.28
Other Intangible Assets	0.34	0.37	0.55	0.58	0.63	0.67
Long-Term Deferred Tax Assets	13.42	17.33	-	-	-	-
Other Long-Term Assets	0.1	0.17	0.04	22.07	0.26	0.32
Total Assets	248.85	257.76	173.29	220.85	247.27	229.79
Accounts Payable	9.93	11.49	5.85	0.19	10.62	13.15
Accrued Expenses	16.23	21.5	13.1	18.9	27.9	21.3
Current Portion of Long-Term Debt	-	-	15.45	37.47	123.51	-
Current Portion of Leases	2.06	2.06	2.06	1.99	0.9	1.75
Current Income Taxes Payable	-	-	-	-	0.5	0.8
Current Unearned Revenue	1.57	1.62	1.23	1.23	1.23	2.56
Other Current Liabilities	4.6	8.89	9.9	15.07	9.76	10.6
Total Current Liabilities	34.39	45.56	47.59	74.85	174.41	50.16
Long-Term Debt	81.98	95.91	95.46	131.36	94.54	239.67
Long-Term Leases	12.74	13.7	15.64	16.32	0.01	0.9
Long-Term Unearned Revenue	10.26	11.39	9.46	10.69	11.93	13.16
Pension & Post-Retirement Benefits	6.32	10.21	15.15	8.34	24.99	27.8
Other Long-Term Liabilities	-	-	0	-0	-	0.16
Total Liabilities	145.69	176.77	183.29	241.56	305.87	331.84
Common Stock	13.31	13.17	13.1	13.09	12.99	11.92
Additional Paid-In Capital	1,051	1,048	1,042	1,037	1,030	982.44
Retained Earnings	-907.49	-923.29	-1,001	-1,011	-1,023	-1,016
Treasury Stock	-51.52	-51.7	-54.01	-56.07	-56.56	-52.77
Comprehensive Income & Other	-1.67	-4.74	-10.21	-3.79	-21.62	-27.25
Shareholders' Equity	103.16	81	-10	-20.72	-58.61	-102.05
Total Liabilities & Equity	248.85	257.76	173.29	220.85	247.27	229.79
Total Debt	96.79	111.67	128.61	187.14	218.96	242.32
Net Cash (Debt)	31.58	9.04	-68.67	-102.48	-70.26	-80.54
Net Cash Per Share	2.28	0.65	-5.66	-8.58	-6.01	-7.83
Filing Date Shares Outstanding	12.28	12.13	12	11.95	11.84	10.87
Total Common Shares Outstanding	12.28	12.13	12	11.95	11.84	10.87
Working Capital	183.07	175.35	104.55	100.51	66.66	173.37
Book Value Per Share	8.40	6.68	-0.83	-1.73	-4.95	-9.39
Tangible Book Value	102.82	80.63	-10.55	-21.29	-59.24	-102.72
Tangible Book Value Per Share	8.37	6.65	-0.88	-1.78	-5.00	-9.45
Land	-	-	-	-	-	0.2
Buildings	-	-	-	-	-	1.9
Machinery	13.69	13.61	12.86	12.98	16.62	24.63
Leasehold Improvements	2	1.8	1.8	1.8	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.